NCT01655043View on ClinicalTrials.gov

Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Myocardial Ischemia
Interventions
DRUG

Regadenoson

Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.

DRUG

gadofoveset trisodium

All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

Astellas Pharma Global Development, Inc.

INDUSTRY

lead

Northwestern University

OTHER

NCT01655043 - Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI | Biotech Hunter | Biotech Hunter